Based on these exciting outcomes, a phase 1 clinical trial was conducted in the Netherlands to assess the clinical safety and feasibility of proinsulin peptide-loaded tolDCs in nine patients with longstanding type 1 diabetes [156]. This evidence concerns the gene INS and type 1 diabetes mellitus.